| Expression pattern: |
UP |
| Associated gene: |
Cdc25B, Cdc2, Ago2 |
| Associated microRNA: |
miR-338-3p |
| Biological function: |
Promotes G2/M transition and cell proliferation; inhibits apoptosis in prostate cancer cells. |
| Molecular mechanism: |
Acts as a miRNA sponge (ceRNA) for miR-338-3p, increasing Cdc25B and Cdc2 expression to facilitate G2/M transition. |
| Biological pathway or process: |
cell cycle (promotes); proliferation (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; Bioinformatics Analysis; RNA Pull-Down; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Western Blot; IHC (Immunohistochemistry); Clinical Sample Validation |
| Clinical significance: |
High circHIPK3 expression is associated with higher Gleason scores in PCa patients. |
| Description: |
CircHIPK3 is upregulated in prostate cancer tissues/cells and promotes proliferation by facilitating the G2/M transition. It functions mainly in the cytoplasm as a ceRNA that sponges miR-338-3p, thereby relieving repression of Cdc25B (and increasing Cdc2), which drives cell-cycle progression. |
| Confidence score: |
0.8032 |